FreeTheAI

Pfizer, Inc.

PFE · NYSE · USD

$27.82

−0.18 −0.64%todayNot financial advice.

PFE Price chart 6M
Open
27.90
Day range
27.48 - 28.00
52-week range
23.62 - 29.21
Volume
44.43M
Market cap
158.56B
P/E ratio
36.84
EPS
0.76
Dividend yield
6.14%
Beta
0.44

Performance

W

−2.20%

1M

−0.70%

3M

+14.27%

6M

+1.83%

YTD

+11.37%

Y

+5.30%

5Y

−34.89%

All

+6,376.79%

In the news

  1. Oct 8

    FDA Approves Pfizer's Tukysa Combination for Frontline Maintenance of HER2-Positive Breast Cancer

    Pfizer received FDA approval for a Tukysa combination to treat HER2-positive breast cancer, expanding its oncology portfolio and frontline options.

    Company news

  2. Oct 8

    Cantor Fitzgerald Raises Price Targets for Eli Lilly, Pfizer, and Merck

    Cantor Fitzgerald raised price targets for Eli Lilly, Pfizer, and Merck, highlighting drug pipelines and growth prospects.

    Analyst ratings

  3. Oct 8

    Pfizer to Cut 330 Jobs and Close Penicillin Unit at Italian Plant

    Pfizer Inc. will close its penicillin department and lay off 330 workers at its Catania plant in Sicily as part of a restructuring plan.

    Company news

  4. Oct 7

    FDA Approves Pfizer Breast Cancer Drug Combination for First-Line Maintenance Therapy

    Pfizer's TUKYSA regimen won FDA approval as a first-line maintenance treatment for metastatic breast cancer, delaying disease progression.

    Company news

  5. Oct 7

    FDA Approves Pfizer's Tukysa Combination for Front-Line Breast Cancer Treatment

    The FDA approved Pfizer's Tukysa combination regimen for front-line breast cancer treatment, expanding the drug's market reach.

    Company news

  6. Oct 7

    FDA Approves Pfizer's TUKYSA Combination for Front-Line Metastatic Breast Cancer

    Pfizer's TUKYSA combination has been approved by the FDA as a front-line maintenance therapy to delay disease progression in HER2-positive breast cancer.

    Company news

  7. Oct 7

    Pfizer Wins FDA Approval for TUKYSA as Front-Line Breast Cancer Maintenance Treatment

    Pfizer (PFE) secured FDA approval for TUKYSA as a front-line breast cancer maintenance therapy, expanding its oncology revenue potential.

    Company news

Embed on your site

Embed docs

Add a live price card or a chart to any page. Free, no sign-up; cards refresh every minute and link back here.

<iframe src="https://stocks.freetheai.org/embed/NYSE-PFE" width="340" height="170" style="border:0;max-width:100%" loading="lazy" title="Pfizer, Inc. (PFE) - FreeTheAI Stocks"></iframe>
<p style="font-size:12px"><a href="https://stocks.freetheai.org/symbols/NYSE-PFE">PFE stock price</a> by FreeTheAI Stocks</p>